Current Approaches for Glioma Gene Therapy and Virotherapy

Autores
Banerjee, Kaushik; Núñez Aguilera, Felipe Javier; Haase, Santiago; McClellan, Brandon L.; Faisal, Syed M.; Carney, Stephen V.; Yu, Jin; Alghamri, Mahmoud S.; Asad, Antonela Sofía; Nicola Candia, Alejandro Javier; Varela, Maria Luisa; Candolfi, Marianela; Lowenstein, Pedro R.; Castro, Maria G.
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM.
Fil: Banerjee, Kaushik. University of Michigan; Estados Unidos
Fil: Núñez Aguilera, Felipe Javier. Fundación Instituto Leloir; Argentina
Fil: Haase, Santiago. University of Michigan; Estados Unidos
Fil: McClellan, Brandon L.. University of Michigan; Estados Unidos
Fil: Faisal, Syed M.. University of Michigan; Estados Unidos
Fil: Carney, Stephen V.. University of Michigan; Estados Unidos
Fil: Yu, Jin. University of Michigan; Estados Unidos
Fil: Alghamri, Mahmoud S.. University of Michigan; Estados Unidos
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Varela, Maria Luisa. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria G.. University of Michigan; Estados Unidos
Materia
FMS-LIKE TYROSINE KINASE 3 LIGAND
GENE THERAPY
GLIOMA
HSV1-TK
IMMUNOTHERAPY
MUTANT IDH1 3
NON-VIRAL VECTORS
VIRAL VECTORS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/214289

id CONICETDig_bb22d3f053796718f76f9f2f328a5226
oai_identifier_str oai:ri.conicet.gov.ar:11336/214289
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Current Approaches for Glioma Gene Therapy and VirotherapyBanerjee, KaushikNúñez Aguilera, Felipe JavierHaase, SantiagoMcClellan, Brandon L.Faisal, Syed M.Carney, Stephen V.Yu, JinAlghamri, Mahmoud S.Asad, Antonela SofíaNicola Candia, Alejandro JavierVarela, Maria LuisaCandolfi, MarianelaLowenstein, Pedro R.Castro, Maria G.FMS-LIKE TYROSINE KINASE 3 LIGANDGENE THERAPYGLIOMAHSV1-TKIMMUNOTHERAPYMUTANT IDH1 3NON-VIRAL VECTORSVIRAL VECTORShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM.Fil: Banerjee, Kaushik. University of Michigan; Estados UnidosFil: Núñez Aguilera, Felipe Javier. Fundación Instituto Leloir; ArgentinaFil: Haase, Santiago. University of Michigan; Estados UnidosFil: McClellan, Brandon L.. University of Michigan; Estados UnidosFil: Faisal, Syed M.. University of Michigan; Estados UnidosFil: Carney, Stephen V.. University of Michigan; Estados UnidosFil: Yu, Jin. University of Michigan; Estados UnidosFil: Alghamri, Mahmoud S.. University of Michigan; Estados UnidosFil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Varela, Maria Luisa. University of Michigan; Estados UnidosFil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Lowenstein, Pedro R.. University of Michigan; Estados UnidosFil: Castro, Maria G.. University of Michigan; Estados UnidosFrontiers Media2021-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/214289Banerjee, Kaushik; Núñez Aguilera, Felipe Javier; Haase, Santiago; McClellan, Brandon L.; Faisal, Syed M.; et al.; Current Approaches for Glioma Gene Therapy and Virotherapy; Frontiers Media; Frontiers in Molecular Neuroscience; 14; 3-2021; 1-301662-5099CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fnmol.2021.621831/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fnmol.2021.621831info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:02:50Zoai:ri.conicet.gov.ar:11336/214289instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:02:51.008CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Current Approaches for Glioma Gene Therapy and Virotherapy
title Current Approaches for Glioma Gene Therapy and Virotherapy
spellingShingle Current Approaches for Glioma Gene Therapy and Virotherapy
Banerjee, Kaushik
FMS-LIKE TYROSINE KINASE 3 LIGAND
GENE THERAPY
GLIOMA
HSV1-TK
IMMUNOTHERAPY
MUTANT IDH1 3
NON-VIRAL VECTORS
VIRAL VECTORS
title_short Current Approaches for Glioma Gene Therapy and Virotherapy
title_full Current Approaches for Glioma Gene Therapy and Virotherapy
title_fullStr Current Approaches for Glioma Gene Therapy and Virotherapy
title_full_unstemmed Current Approaches for Glioma Gene Therapy and Virotherapy
title_sort Current Approaches for Glioma Gene Therapy and Virotherapy
dc.creator.none.fl_str_mv Banerjee, Kaushik
Núñez Aguilera, Felipe Javier
Haase, Santiago
McClellan, Brandon L.
Faisal, Syed M.
Carney, Stephen V.
Yu, Jin
Alghamri, Mahmoud S.
Asad, Antonela Sofía
Nicola Candia, Alejandro Javier
Varela, Maria Luisa
Candolfi, Marianela
Lowenstein, Pedro R.
Castro, Maria G.
author Banerjee, Kaushik
author_facet Banerjee, Kaushik
Núñez Aguilera, Felipe Javier
Haase, Santiago
McClellan, Brandon L.
Faisal, Syed M.
Carney, Stephen V.
Yu, Jin
Alghamri, Mahmoud S.
Asad, Antonela Sofía
Nicola Candia, Alejandro Javier
Varela, Maria Luisa
Candolfi, Marianela
Lowenstein, Pedro R.
Castro, Maria G.
author_role author
author2 Núñez Aguilera, Felipe Javier
Haase, Santiago
McClellan, Brandon L.
Faisal, Syed M.
Carney, Stephen V.
Yu, Jin
Alghamri, Mahmoud S.
Asad, Antonela Sofía
Nicola Candia, Alejandro Javier
Varela, Maria Luisa
Candolfi, Marianela
Lowenstein, Pedro R.
Castro, Maria G.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv FMS-LIKE TYROSINE KINASE 3 LIGAND
GENE THERAPY
GLIOMA
HSV1-TK
IMMUNOTHERAPY
MUTANT IDH1 3
NON-VIRAL VECTORS
VIRAL VECTORS
topic FMS-LIKE TYROSINE KINASE 3 LIGAND
GENE THERAPY
GLIOMA
HSV1-TK
IMMUNOTHERAPY
MUTANT IDH1 3
NON-VIRAL VECTORS
VIRAL VECTORS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM.
Fil: Banerjee, Kaushik. University of Michigan; Estados Unidos
Fil: Núñez Aguilera, Felipe Javier. Fundación Instituto Leloir; Argentina
Fil: Haase, Santiago. University of Michigan; Estados Unidos
Fil: McClellan, Brandon L.. University of Michigan; Estados Unidos
Fil: Faisal, Syed M.. University of Michigan; Estados Unidos
Fil: Carney, Stephen V.. University of Michigan; Estados Unidos
Fil: Yu, Jin. University of Michigan; Estados Unidos
Fil: Alghamri, Mahmoud S.. University of Michigan; Estados Unidos
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Varela, Maria Luisa. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria G.. University of Michigan; Estados Unidos
description Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM.
publishDate 2021
dc.date.none.fl_str_mv 2021-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/214289
Banerjee, Kaushik; Núñez Aguilera, Felipe Javier; Haase, Santiago; McClellan, Brandon L.; Faisal, Syed M.; et al.; Current Approaches for Glioma Gene Therapy and Virotherapy; Frontiers Media; Frontiers in Molecular Neuroscience; 14; 3-2021; 1-30
1662-5099
CONICET Digital
CONICET
url http://hdl.handle.net/11336/214289
identifier_str_mv Banerjee, Kaushik; Núñez Aguilera, Felipe Javier; Haase, Santiago; McClellan, Brandon L.; Faisal, Syed M.; et al.; Current Approaches for Glioma Gene Therapy and Virotherapy; Frontiers Media; Frontiers in Molecular Neuroscience; 14; 3-2021; 1-30
1662-5099
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fnmol.2021.621831/full
info:eu-repo/semantics/altIdentifier/doi/10.3389/fnmol.2021.621831
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613837240664064
score 13.070432